The Sheffield IBS Trial

Clinical trial: a multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study

SUMMARY

This double-blind, placebo-controlled study examines the role of probiotic administration in the prevention of C. difficile-associated diarrhoea (CDAD) in elderly patients receiving antibiotic therapy.​
Results showed that Lab4 probiotics reduced the incidence of Clostridium difficile diarrhoea in these patients.​
46% of patients supplemented with Lab4 probiotics were positive for Clostridium difficile toxin compared to 78% of patients in the placebo group

Aim

This randomised, double-blind, placebo controlled study investigated the effect of supplementation with Lab4 probiotics on the symptoms of IBS.

Method

Results

  • The participants taking the Lab4 probiotics (Group 2) showed significant reduction in Total IBS symptoms compared to placebo (Group 1, *P<0.05).
  • The reductions in days with pain and bloating were achieved with Group 2.
  • Satisfaction with bowel habit and quality of life were significantly improved in Group 2 (reduction in the symptom severity scores).
  • Improvement in IBS symptoms diminished quickly when the Lab4 probiotic supplementation was discontinued (week 10, 2 weeks after the intervention).

Conclusion

The Lab4 probiotics significantly reduced total symptoms and improved quality of life in diagnosed IBS sufferers. Continued supplementation was considered necessary to sustain this improvement.

Reference

Williams EA et al 2008. Clinical trial: a multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study. Alimentary Pharmacology & Therapeutics, 29: 97-103
Scroll to Top